‘Case appears clearcut’: Top-down therapy should be ‘standard of care’ for new Crohn’s
Early treatment with infliximab plus an immunomodulator resulted in more frequent steroid-free and surgery-free remission at 1 year compared with conventional therapy among patients with newly diagnosed Crohn’s disease, researchers reported. “The ability to predict which patients would benefit from early advanced therapies would enable targeting of these treatments to patients who